Trial Evaluating the Efficacy and Safety of Patiromer in Chinese Subjects

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 262 participants.

Also called NCT05136664

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 262 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05136664
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05136664. Randomized; single masking; primary purpose treatment. Start 2022-02-10 (actual); primary completion 2025-11-18 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Trial Evaluating the Efficacy and Safety of Patiromer in Chinese Subjects
Acronym
Patiromer JADE
Condition
Hyperkalemia
Condition
Renal Insufficiency, Chronic
Intervention (Drug)
Patiromer Powder for Oral Suspension (Part A)
Intervention (Drug)
Placebo (Part B)
Intervention (Drug)
Patiromer Powder for Orals Suspension (Part B)
Lead sponsor
Vifor Fresenius Medical Care Renal Pharma (class: industry)
Collaborator
Tigermed Consulting Co., Ltd (class: industry)

Record details

Record id
cardio:ct-nct05136664
Content hash
e7b5b2ccbf7a7bcbe6e24de3e29ac5409577e2747ae06f01c403891b728a74f1